Cough Variant Asthma
Conditions
Brief summary
Cough variant asthma (CVA), subtype of bronchial asthma, is considered to be one of the most common causes of chronic cough in different cough guidelines of United States, Europe, China and other countries. From a multicenter survey in China, over one third of chronic cough is caused by CVA, which is higher than western countries. CVA differs from classic asthma, usually manifesting a symptom of only coughing without wheezing or dyspnea and particularly coughing at night. With less clinical manifestation and medical intervention, CVA patients are easily be neglected and misdiagnosed, and 30-40% of them will develop to typical asthma in the next few years. Currently there's no specific therapy recommendation for CVA in GINA. Although cough guidelines in China recommend that CVA patients should be treated as typical asthma, no recommendation on details about ICS/LABA dosage and duration. There are only a few sporadic CVA therapy researches with small sample size. Two studiesfound that CVA patients can't get cough symptom relief even after treating by low dose of ICS/LABA for 3 months. Some patients' cough symptom relapses during the 24-week follow-up phase after treating by ICS/LABA for 3 months. Overall, the best treatment of CVA is not yet clear. GINA 2018 emphasize that asthma need long-term management. Euro-SMART study found that budesonide/formoterol 2 inhalation twice daily plus as needed can reduce daytime asthma symptoms and night-time awakenings, as well as reduce exacerbation risk more than 1 inhalation twice daily. Based on the above reasons, We assume that increase the dosage of ICS/LABA can decrease relapse rate in CVA patients with severe cough. This multi-center, randomized, controlled clinical trial can help to clarify the best dosage of budesonide/formoterol of CVA in China.
Interventions
DRUGbudesonide/formoterol
apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
Sponsors
Shanghai Tongji Hospital, Tongji University School of Medicine
Tongji Hospital
Zunyi Medical College
Central South University
China-Japan Friendship Hospital
Shenzhen People's Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Outpatients, with age ≥18，≤70 years old. * Diagnose with CVA * CSS(cough symptom score, daytime + nighttime) ≥ 3 points
Exclusion criteria
* Participated in any interventional clinical trial during the last 90 days. * Pregnancy * Associated with a clear history of other lung diseases, or combined with other systems severe illness. * A abuse history of alcohol or narcotic drug, or have a mental history, confrontation personality, adverse motives, suspicious or other emotional or intellectual problems that may affect the informed validity of the study * With a history of upper respiratory tract infection acute exacerbation within 4 weeks before enrolment. * Clinical abnormalities associated with symptoms in chest radiology. * Smokers * On medications of ACEI or ARB * Not suitable for study observation judged by investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the proportion of CVA patient with symptom relapse | during 6-months' follow-up phase | Relapse rate during the 6-months' follow-up phase after treating by different doses of budesonide/formoterol for 3 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the proportion of CVA patient with symptom relief | after treating by different doses of budesonide/formoterol for 3 months. | symptom relief rate after treating by different doses of budesonide/formoterol for 3 months. |
Other
| Measure | Time frame | Description |
|---|---|---|
| change in lung function | during 6-months' follow-up phase | value of pulmonary function index such as FEV1% Pred, FVC% Pred, PD20-FEV1 and PEF |
| assess different phenotypes of CVA | during 6-months' follow-up phase | investigate inflammation characteristics consist of differential count of inflammatory cells in induced sputum |
| assess safety of different doses of budesonide/formoterol | during 6-months' follow-up phase | evaluate adverse events of different doses of budesonide/formoterol |
Countries
China
Contacts
Primary ContactWen Li, Prof.
Outcome results
None listed